Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Noxopharm Ltd. ( (AU:NOX) ).
Noxopharm Limited has released its Annual Report for the year ending June 30, 2025, highlighting significant progress in its clinical trials and growing interest in its Sofra™ technology platform. The company has successfully advanced its first asset, SOF-SKN™, from preclinical studies to clinical trials, demonstrating its ability to quickly translate research into real-world applications. This milestone has attracted considerable external stakeholder interest, enhancing Noxopharm’s industry positioning and potential impact on cancer and inflammation treatment.
More about Noxopharm Ltd.
Noxopharm Limited is an Australian clinical-stage biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company leverages its proprietary Sofra™ and Chroma™ technology platforms to enhance mRNA medicines and develop oncology treatments, working with strategic partnerships and in-house capabilities.
Average Trading Volume: 265,437
Technical Sentiment Signal: Buy
Current Market Cap: A$30.68M
Find detailed analytics on NOX stock on TipRanks’ Stock Analysis page.